Key Highlights
- Eli Lilly will acquire Centessa Pharmaceuticals through a cash offer of $38 per share, representing approximately $6.3 billion in value
- An additional contingent value right (CVR) worth approximately $9 per share could elevate the transaction value to $7.8 billion
- Centessa’s U.S. shares soared 46% during premarket hours following the announcement
- The deal centers on Centessa’s pipeline of sleep-wake disorder therapies
- Lilly simultaneously revealed a $2.75 billion partnership with Insilico Medicine for AI-driven drug discovery
Eli Lilly revealed Tuesday its plan to purchase Centessa Pharmaceuticals through a transaction valued at approximately $6.3 billion. The pharmaceutical giant is offering $38 per share in cash for the Frankfurt-traded biotechnology company.
The acquisition includes one non-transferrable contingent value right valued at around $9 per share. Should this CVR be triggered, the complete transaction value would climb to roughly $7.8 billion.
Centessa’s U.S.-traded shares experienced a 46% spike in premarket activity after the deal became public. This substantial increase demonstrates the significant premium Lilly is willing to pay for access to Centessa’s sleep disorder treatment portfolio.
Centessa Pharmaceuticals plc, CNTA
The transaction focuses on sleep-wake disorder therapeutics, representing a new therapeutic area for Lilly. Centessa offers a specialized development portfolio that Lilly believes holds strong commercialization potential.
This acquisition represents Lilly’s second significant transaction announcement within two consecutive days. The company revealed Monday a $2.75 billion collaboration with Insilico Medicine aimed at commercializing AI-discovered pharmaceutical compounds worldwide.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s strategy of combining conventional pharmaceutical development with cutting-edge technology platforms.
Strategic Entry Into Sleep Disorder Market
The Centessa purchase represents a deliberate strategic expansion into sleep-wake disorder treatments. This therapeutic category has garnered increasing interest from leading pharmaceutical companies over recent years.
Centessa has been advancing orexin receptor agonists, a drug class designed to activate the brain’s wake-promoting pathways. These compounds show promise for addressing conditions including narcolepsy and excessive daytime sleepiness.
Lilly’s decision to offer a substantial premium indicates strong belief in the pipeline’s clinical prospects. The CVR mechanism ensures portions of the total payment depend on achieving specified future development objectives.
Dual Announcements Mark Active Expansion Period
The Insilico collaboration, revealed Monday, contributes another strategic element to Lilly’s recent business development activity. Insilico employs AI technology to engineer novel drug candidates, a methodology that may significantly reduce early development timelines.
Lilly announced it will license and advance therapeutic compounds identified through Insilico’s computational platform. Complete financial details beyond the $2.75 billion primary figure remain undisclosed.
Two major deal announcements within a 24-hour period represents uncommon activity level even for an organization of Lilly’s magnitude. LLY shares traded approximately 1% higher Tuesday morning as market participants evaluated both transactions.
Centessa’s Frankfurt-listed equity also climbed substantially after the announcement, with the cash offer positioned well above recent trading levels.
